Catheterized guinea pigs infected with Ebola Zaire virus allows safer sequential sampling to determine the pharmacokinetic profile of a phosphatidylserine-targeting monoclonal antibody
- Stuart Dowall(corresponding author),
- Irene Taylor,
- Paul Yeates,
- Leonie Smith,
- Antony Rule,
- ,
- ,
- Public Health England,
- ,
- Peregrine Pharmaceuticals, Inc.,
Research Output:
Contribution to journal
Article
Research
Peer-reviewAbstract
Sequential sampling from animals challenged with highly pathogenic organisms, such as haemorrhagic fever viruses, is required for many pharmaceutical studies. Using the guinea pig model of Ebola virus infection, a catheterized system was used which had the benefits of allowing repeated sampling of the same cohort of animals, and also a reduction in the use of sharps at high biological containment. Levels of a PS-targeting antibody (Bavituximab) were measured in Ebola-infected animals and uninfected controls. Data showed that the pharmacokinetics were similar in both groups, therefore Ebola virus infection did not have an observable effect on the half-life of the antibody.
Research Output Information
Output type
Research Output:
Contribution to journal
Article
Research
Peer-reviewOriginal language
EnglishPages from-to (Number of pages)
Pages 108-111 (4 pages)Journal (Volume, Issue Number)
Antiviral Research (Volume 97, Issue 2)Publication milestones
- Published - 02/2013
Publication status
Published - 02/2013
ISSN
0166-3542Publication IDs
- Scopus: 84871894016
- PubMed: 23165089
Sustainable Development Goals
- SDG 3 Good Health and Well
